Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Trial Details

NCT ID
NCT05413850
Phase
PHASE1 / PHASE2
Sponsor
Blue Earth Therapeutics Ltd
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Lutetium (177Lu) rhPSMA-10.1 Injection
  • 18F-rhPSMA-7.3 injection (in phase 1 only)
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366
  • Miami, Florida, United States|25.77427,-80.19366
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Male subjects, 18 years of age or older with histologically confirmed adenocarcinoma of the prostate.
  • Serum testosterone levels \<50 ng/dL (1.73 nmol/L) after surgical or continued chemical castration.
  • Presence of disease target or non target lesions (per RECIST v1.1) on CT/MRI and/or presence of disease on full body 99mTc bone scan performed with…
  • Positive disease expression of PSMA as confirmed on PSMA PET/CT scan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →